|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:XYLT1-GALNT6 (FusionGDB2 ID:99182) |
Fusion Gene Summary for XYLT1-GALNT6 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: XYLT1-GALNT6 | Fusion gene ID: 99182 | Hgene | Tgene | Gene symbol | XYLT1 | GALNT6 | Gene ID | 64131 | 11226 |
| Gene name | xylosyltransferase 1 | polypeptide N-acetylgalactosaminyltransferase 6 | |
| Synonyms | DBQD2|PXYLT1|XT-I|XT1|XTI|XYLTI|xylT-I | GALNAC-T6|GalNAcT6 | |
| Cytomap | 16p12.3 | 12q13.13 | |
| Type of gene | protein-coding | protein-coding | |
| Description | xylosyltransferase 1beta-D-xylosyltransferase 1peptide O-xylosyltransferase 1xylosyltransferase Ixylosyltransferase iota | polypeptide N-acetylgalactosaminyltransferase 6GalNAc transferase 6UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 6UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 6UDP-N-acetyl-alpha-D-galactosamine:polypept | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | . | Q8NCL4 | |
| Ensembl transtripts involved in fusion gene | ENST00000261381, ENST00000568226, | ENST00000543196, ENST00000356317, ENST00000603203, | |
| Fusion gene scores | * DoF score | 10 X 8 X 4=320 | 3 X 3 X 2=18 |
| # samples | 10 | 3 | |
| ** MAII score | log2(10/320*10)=-1.67807190511264 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: XYLT1 [Title/Abstract] AND GALNT6 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | XYLT1(17292069)-GALNT6(51771151), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | XYLT1 | GO:0030166 | proteoglycan biosynthetic process | 11087729 |
| Fusion gene breakpoints across XYLT1 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across GALNT6 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | SARC | TCGA-DX-A1KU-01A | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - |
Top |
Fusion Gene ORF analysis for XYLT1-GALNT6 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000261381 | ENST00000543196 | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - |
| In-frame | ENST00000261381 | ENST00000356317 | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - |
| 5CDS-intron | ENST00000261381 | ENST00000603203 | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - |
| intron-3CDS | ENST00000568226 | ENST00000543196 | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - |
| intron-3CDS | ENST00000568226 | ENST00000356317 | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - |
| intron-intron | ENST00000568226 | ENST00000603203 | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000261381 | XYLT1 | chr16 | 17292069 | - | ENST00000543196 | GALNT6 | chr12 | 51771151 | - | 5884 | 1374 | 13 | 2751 | 912 |
| ENST00000261381 | XYLT1 | chr16 | 17292069 | - | ENST00000356317 | GALNT6 | chr12 | 51771151 | - | 3378 | 1374 | 13 | 2751 | 912 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000261381 | ENST00000543196 | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - | 0.003056144 | 0.9969439 |
| ENST00000261381 | ENST00000356317 | XYLT1 | chr16 | 17292069 | - | GALNT6 | chr12 | 51771151 | - | 0.005902445 | 0.9940976 |
Top |
Fusion Genomic Features for XYLT1-GALNT6 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for XYLT1-GALNT6 |
| Go to FGviewer for the breakpoints of chr16:17292069-chr12:51771151 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | GALNT6 |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. May participate in synthesis of oncofetal fibronectin. Has activity toward Muc1a, Muc2, EA2 and fibronectin peptides. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | XYLT1 | chr16:17292069 | chr12:51771151 | ENST00000261381 | - | 5 | 12 | 390_392 | 429.6666666666667 | 960.0 | Region | UDP-xylose binding |
| Hgene | XYLT1 | chr16:17292069 | chr12:51771151 | ENST00000261381 | - | 5 | 12 | 1_17 | 429.6666666666667 | 960.0 | Topological domain | Cytoplasmic |
| Hgene | XYLT1 | chr16:17292069 | chr12:51771151 | ENST00000261381 | - | 5 | 12 | 18_38 | 429.6666666666667 | 960.0 | Transmembrane | Helical%3B Signal-anchor for type II membrane protein |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000356317 | 2 | 12 | 496_622 | 163.66666666666666 | 623.0 | Domain | Ricin B-type lectin | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000543196 | 1 | 11 | 496_622 | 163.66666666666666 | 623.0 | Domain | Ricin B-type lectin | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000356317 | 2 | 12 | 176_285 | 163.66666666666666 | 623.0 | Region | Note=Catalytic subdomain A | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000356317 | 2 | 12 | 348_410 | 163.66666666666666 | 623.0 | Region | Note=Catalytic subdomain B | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000543196 | 1 | 11 | 176_285 | 163.66666666666666 | 623.0 | Region | Note=Catalytic subdomain A | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000543196 | 1 | 11 | 348_410 | 163.66666666666666 | 623.0 | Region | Note=Catalytic subdomain B |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | XYLT1 | chr16:17292069 | chr12:51771151 | ENST00000261381 | - | 5 | 12 | 494_495 | 429.6666666666667 | 960.0 | Region | UDP-xylose binding |
| Hgene | XYLT1 | chr16:17292069 | chr12:51771151 | ENST00000261381 | - | 5 | 12 | 598_599 | 429.6666666666667 | 960.0 | Region | UDP-xylose binding |
| Hgene | XYLT1 | chr16:17292069 | chr12:51771151 | ENST00000261381 | - | 5 | 12 | 39_959 | 429.6666666666667 | 960.0 | Topological domain | Lumenal |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000356317 | 2 | 12 | 1_8 | 163.66666666666666 | 623.0 | Topological domain | Cytoplasmic | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000356317 | 2 | 12 | 29_622 | 163.66666666666666 | 623.0 | Topological domain | Lumenal | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000543196 | 1 | 11 | 1_8 | 163.66666666666666 | 623.0 | Topological domain | Cytoplasmic | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000543196 | 1 | 11 | 29_622 | 163.66666666666666 | 623.0 | Topological domain | Lumenal | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000356317 | 2 | 12 | 9_28 | 163.66666666666666 | 623.0 | Transmembrane | Helical%3B Signal-anchor for type II membrane protein | |
| Tgene | GALNT6 | chr16:17292069 | chr12:51771151 | ENST00000543196 | 1 | 11 | 9_28 | 163.66666666666666 | 623.0 | Transmembrane | Helical%3B Signal-anchor for type II membrane protein |
Top |
Fusion Gene Sequence for XYLT1-GALNT6 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000261381_ENST00000543196_TCGA-DX-A1KU-01A_XYLT1_chr16_17292069_-_GALNT6_chr12_51771151_length(transcript)=5884nt_BP=1374nt GCGGCCGCGGGAGCTGCGGGGAGCGCGGGGGCGGCCCGGAGCGTGCCGGGGTCCCCGCGCCTCGCTCGCCGGCCGCGCTCCGAAGATGGT GGCGGCGCCGTGCGCCCGGAGGCTGGCCCGGCGCTCGCACTCGGCGCTGCTCGCGGCGCTCACGGTGCTGCTGCTGCAGACGCTGGTCGT GTGGAATTTCAGCAGCCTCGACTCCGGGGCCGGGGAGCGCCGCGGGGGCGCAGCGGTCGGCGGCGGGGAGCAGCCGCCCCCGGCCCCGGC CCCGCGCCGGGAGCGCCGGGACCTGCCCGCCGAGCCGGCTGCAGCCCGAGGAGGAGGAGGAGGCGGCGGCGGAGGAGGAGGAGGACGGGG GCCCCAGGCGCGGGCGCGGGGAGGCGGCCCCGGAGAACCGCGGGGACAGCAGCCGGCCAGCCGGGGGGCACTGCCCGCCCGGGCTCTGGA TCCACACCCAAGTCCGCTCATCACCCTGGAGACTCAGGATGGCTACTTTTCTCATCGGCCGAAAGAGAAAGTGCGAACAGACAGCAACAA CGAGAACTCTGTCCCCAAAGACTTTGAGAATGTCGACAACAGCAACTTCGCACCCAGGACTCAAAAGCAGAAGCACCAGCCTGAGTTGGC GAAGAAGCCACCGAGTAGACAGAAGGAGCTTTTGAAAAGGAAGCTGGAACAGCAGGAGAAAGGAAAAGGACATACATTCCCTGGGAAAGG CCCCGGTGAGGTGCTGCCTCCCGGGGACAGAGCCGCAGCCAACAGCAGCCACGGGAAGGATGTGTCCAGACCGCCTCATGCCAGGAAAAC TGGGGGCAGCTCCCCCGAGACCAAGTATGACCAGCCCCCTAAGTGTGACATCTCAGGCAAGGAGGCCATCTCTGCCCTGTCCCGTGCTAA GTCCAAGCACTGCCGCCAGGAGATTGGGGAGACTTACTGCCGCCACAAGTTAGGGCTGCTGATGCCTGAGAAGGTGACTCGGTTCTGCCC CCTCGAGGGTAAAGCCAACAAGAACGTGCAGTGGGACGAGGACTCCGTGGAGTACATGCCAGCCAACCCGGTCAGAATCGCCTTTGTCCT GGTGGTCCACGGCCGTGCCTCTCGGCAGTTGCAGCGCATGTTCAAGGCCATCTACCACAAAGACCACTTCTACTACATCCACGTGGACAA GCGCTCTAATTACCTGCATCGGCAAGTGCTCCAGGTCTCCAGGCAGTACAGCAATGTCCGCGTCACCCCCTGGAGAATGGCCACCATCTG GGGAGGAGCCAGCCTCCTGTCCACCTACCTGCAGAGCATGCGGGACCTCCTGGAGATGACCGACTGGCCCTGGGACTTCTTCATCAACCT GAGTGCGGCCGACTACCCCATCAGGTGTGTGGACCAGAAGTTCCGGCGCTGCCCCCCACTGGCCACCACCAGCGTGATCATTGTGTTCCA CAACGAAGCCTGGTCCACACTGCTGCGAACAGTGTACAGCGTCCTACACACCACCCCTGCCATCTTGCTCAAGGAGATCATACTGGTGGA TGATGCCAGCACAGAGGAGCACCTAAAGGAGAAGCTGGAGCAGTACGTGAAGCAGCTGCAGGTGGTGAGGGTGGTGCGGCAGGAGGAGCG GAAGGGGCTGATCACCGCCCGGCTGCTGGGGGCCAGCGTGGCACAGGCGGAGGTGCTCACGTTCCTGGATGCCCACTGTGAGTGCTTCCA CGGCTGGCTGGAGCCCCTCCTGGCTCGAATCGCTGAGGACAAGACAGTGGTGGTGAGCCCAGACATCGTCACCATCGACCTTAATACTTT TGAGTTCGCCAAGCCCGTCCAGAGGGGCAGAGTCCATAGCCGAGGCAACTTTGACTGGAGCCTGACCTTCGGCTGGGAAACACTTCCTCC ACATGAGAAGCAGAGGCGCAAGGATGAAACCTACCCCATCAAATCCCCGACGTTTGCTGGTGGCCTCTTCTCCATCTCCAAGTCCTACTT TGAGCACATCGGTACCTATGATAATCAGATGGAGATCTGGGGAGGGGAGAACGTGGAAATGTCCTTCCGGGTGTGGCAGTGTGGGGGCCA GCTGGAGATCATCCCCTGCTCTGTCGTAGGCCATGTGTTCCGGACCAAGAGCCCCCACACCTTCCCCAAGGGCACTAGTGTCATTGCTCG CAATCAAGTGCGCCTGGCAGAGGTCTGGATGGACAGCTACAAGAAGATTTTCTATAGGAGAAATCTGCAGGCAGCAAAGATGGCCCAAGA GAAATCCTTCGGTGACATTTCGGAACGACTGCAGCTGAGGGAACAACTGCACTGTCACAACTTTTCCTGGTACCTGCACAATGTCTACCC AGAGATGTTTGTTCCTGACCTGACGCCCACCTTCTATGGTGCCATCAAGAACCTCGGCACCAACCAATGCCTGGATGTGGGTGAGAACAA CCGCGGGGGGAAGCCCCTCATCATGTACTCCTGCCACGGCCTTGGCGGCAACCAGTACTTTGAGTACACAACTCAGAGGGACCTTCGCCA CAACATCGCAAAGCAGCTGTGTCTACATGTCAGCAAGGGTGCTCTGGGCCTTGGGAGCTGTCACTTCACTGGCAAGAATAGCCAGGTCCC CAAGGACGAGGAATGGGAATTGGCCCAGGATCAGCTCATCAGGAACTCAGGATCTGGTACCTGCCTGACATCCCAGGACAAAAAGCCAGC CATGGCCCCCTGCAATCCCAGTGACCCCCATCAGTTGTGGCTCTTTGTCTAGGACCCAGATCATCCCCAGAGAGAGCCCCCACAAGCTCC TCAGGAAACAGGATTGCTGATGTCTGGGAACCTGATCACCAGCTTCTCTGGAGGCCGTAAAGATGGATTTCTAAACCCACTGGGTGGCAA GGCAGGACCTTCCTAATCCTTGCAACAACATTGGGCCCATTTTCTTTCCTTCACACCGATGGAAGAGACCATTAGGACATATATTTAGCC TAGCGTTTTCCTGTTCTAGAAATAGAGGCTCCCAAAGTAGGGAAGGCAGCTGGGGGAGGGTTCAGGGCAGCAATGCTGAGTTCAAGAAAA GTACTTCAGGCTGGGCACAGTGGCTCATGCCTGAAATCCTAGCACTTTGGGAAGACAATGTGGGAGAATGGCTTGAGCCCAGGAGTTCAA GACCGGCCTGAGCAACATAGTGAGGATCCCATCTCTACGCCCACCCTCCCCCCGGCAAAAAAAAAAAGCTGGGTATGGTGGCTTATGCCT GTAGTCGCAGCTACTCAGAAGGCTGAGGTGGGAGGATTGCTTGTTCCCCGGAGGTTGAAGCTACAGTGAGCCTTGATTGTGTCACTGCAC TCCAGCCTGGGCAACAGGTAAGACTCTGTCTCAAAAAAAAACAAAAAAGAAGAAGAAAAGTACTTCTACAGCCATGTCCTATTCCTTGAT CATCCAAAGCACCTGCAGAGTCCAGTGAAATGATATATTCTGGCTGGGCACAGTGGCTCACACCTGTAATCCTAGCACTTTGGGAGGCCA AGGCAGGTGGATCACCTGAGGTCAGAAGTTTGAAACCAGCCTGGACTACATGGTGAAACTCCATCTCTACTAAAAGTACAAAAATTAGCT GGGCATGATGGCACGCACCTGCAGTCCCAGCTACTTGGGAGGCTGAGGCAGGAGAATCACTCGAACCCAGGAGGCAGAGGTTGCAGTGAG CCAAGACAGCACCATTGCACCCCAGCCTGAGCAACAAGAGCGAAACTCCATCTCAGGAAAAAAAAAAAAAAAAAAAGTATATTCTAACAG ACAGATCAGAGGTCTAAGAGATCCTCCCTTGCTATTATTACCTGAAGTCTGTAGAACTGTTTACAGATATCTCCTTGACAGGTGTCCTTT ATCTTACTTTATCTGTACAGTAATCCTGTGAGAAAGACAGGACAGAAACCACTGTGCCTATTTTACAGATACGAAAACTGAGACACAGGT AAAGGGGCTTGTCTGTAGTCCCATAGCTAGCAGATGGCTGGAGCCAAGACTGAGGCTCGTTCTTCAATGCTGAGCCAGGGCTCCTTCCGC TGCACCACAAGAACGCTAGACCACTCGCCACCAGCCTTCTCATTCCCTCTTCCTCCATTCTAATCATTTCTAGCTGGCTGGCCTCCACAG AGCATAGGAAAACAGCCAGGGCCGGGCACGGTGGCTCATGCCTGTAATCTCAACACTCTGGGAGGCCGAGCCGGGTGGATAACCTGAGGT CAGGAATTCGAGACCAGCCTGGCCAACATGGTAAAACCCCATCTCTACTAAAAATATAAAAATTAGCCAGGCATGGTGGCGCACACCTGT AATCCCAGCTACTCAAGAGGCTGAGGCAGGAGAATTGCTTAAATCTGGGAGGCGGAAGTTGCAGTGAGCCAAGATCGCGCCACTGAACTC CAGCCTAGGCAACAAGAGCAAAACTCCATCTCCAAAAAAAAGAAAGGAAAAACAGGGCCAGGTAGCCATTGTGGAGAGAGCACACTTAGG AATCCTGGGATGTTAGTGTTAAAAGAAAGCTCCTGGAGCCAGTGATTCTCAGGTTTGTCCCAGAACCCTTTTTTCTAAGCCCCATATAAA AGGTAGATTAAAAAAACAAAGTAGCATGAGTGAAATTGAGAGAGGGACAGGTAATGCCTTCCAGCCCCTAACTTCTAACAATCTGGAAGC ACAACGTGAAAATCACGTAGCCCAACCCTATCATTTTCATATTATGAAACTGAGTCCAGGTAAGTGAATCTGTCCAAGGTCACCCAGCAA GGTATCAGTAGCCCTGAGGGTAAGGACTCTGATAAGGCTCGGGAGGGTCCTGGAAAGCCTGAGGCGGCAGGAAGAGTGTGCAGAGTTGAG CGTGTCTGGAAGGCTGATCCACTGCTGGGCCCACATCAAAGCCCCCATGGGGAGCAGACCCGACTGCACATGGCTCTTTTGCTGGAAGAA GAGCATGGCTGCGCAGAGGACTAAAATTTCATCTGGGAAGGCTTCTTTTGACTGTCAGTAGCAGGATGTCACCAGATGAGGGTGCTATGG GACCACAGCTGTCTTTGTTCCCATTGCAACTCAACCCTGCGGGAGGCCGCCTACATCCCTGAGAGCCTTCTGGAGCCTACAGAGGAGACA TTGGCCAGCCAAAAGGAAAGGAGTGGCCAGGGTACGACCTGGAGTAGGGAAGGGAAAAAGTTCCCGGAAAGAAGAGAATTGGATGAGAGG TCTCAGTGGAAATAAAGGTTTTCTGGCATTGGTCAAGGAAACTCGCGTTGTGTTCTCTTACCTGTGTTGTCCCTTAGCTGAATCAGTTGA TTTGGGCTATGAAGAACCACACACATCTGAAAAGTTCTGTTACAGCCACTGTCTCATGTCCCCAAACATTCTCTGGCCCTAAATCTAGCT TATGTATTGTGTCAAGCACGTGGAGACGTGAGACGTCAAACGAGGTCCTGTCCCCGTGGAACTCACACGCTAAATGTAAGCAAATCATAG CAAGCCTGGAGATGCTCCAAGAGGTGCTGGATGAGTTAGAAGGAGCAATTCCTTCCACTTAGGGAATCAGATAAGGCCTCACAAAGATGG CAATGTTTGACCTAAGACCTCGGAAGATGAGTCCTCAGATGGGAAGGGCTCAATAAGCAGAGTTGTTACACAGGCAGCAGCCTGGCAGGA GCAAAGCCACAGAGGACATGTGGCCCCAGTGGGTCTGAGAAACCCAGAGGACATTGGGGTGAGGGAGTGACTGGTGTAGAAGCTGGAAGA TCAGAGTTACATCATGAATTTCAGGGGCCCTAGGCACTTTAGCCTTCACGGAGCTCTTGCTCCATTCAAAAAAAAATTAATGTTATGACT >In-frame_ENST00000261381_ENST00000543196_TCGA-DX-A1KU-01A_XYLT1_chr16_17292069_-_GALNT6_chr12_51771151_length(amino acids)=912AA_start in transcript=13_stop in transcript=2751 MRGARGRPGACRGPRASLAGRAPKMVAAPCARRLARRSHSALLAALTVLLLQTLVVWNFSSLDSGAGERRGGAAVGGGEQPPPAPAPRRE RRDLPAEPAAARGGGGGGGGGGGGRGPQARARGGGPGEPRGQQPASRGALPARALDPHPSPLITLETQDGYFSHRPKEKVRTDSNNENSV PKDFENVDNSNFAPRTQKQKHQPELAKKPPSRQKELLKRKLEQQEKGKGHTFPGKGPGEVLPPGDRAAANSSHGKDVSRPPHARKTGGSS PETKYDQPPKCDISGKEAISALSRAKSKHCRQEIGETYCRHKLGLLMPEKVTRFCPLEGKANKNVQWDEDSVEYMPANPVRIAFVLVVHG RASRQLQRMFKAIYHKDHFYYIHVDKRSNYLHRQVLQVSRQYSNVRVTPWRMATIWGGASLLSTYLQSMRDLLEMTDWPWDFFINLSAAD YPIRCVDQKFRRCPPLATTSVIIVFHNEAWSTLLRTVYSVLHTTPAILLKEIILVDDASTEEHLKEKLEQYVKQLQVVRVVRQEERKGLI TARLLGASVAQAEVLTFLDAHCECFHGWLEPLLARIAEDKTVVVSPDIVTIDLNTFEFAKPVQRGRVHSRGNFDWSLTFGWETLPPHEKQ RRKDETYPIKSPTFAGGLFSISKSYFEHIGTYDNQMEIWGGENVEMSFRVWQCGGQLEIIPCSVVGHVFRTKSPHTFPKGTSVIARNQVR LAEVWMDSYKKIFYRRNLQAAKMAQEKSFGDISERLQLREQLHCHNFSWYLHNVYPEMFVPDLTPTFYGAIKNLGTNQCLDVGENNRGGK PLIMYSCHGLGGNQYFEYTTQRDLRHNIAKQLCLHVSKGALGLGSCHFTGKNSQVPKDEEWELAQDQLIRNSGSGTCLTSQDKKPAMAPC -------------------------------------------------------------- >In-frame_ENST00000261381_ENST00000356317_TCGA-DX-A1KU-01A_XYLT1_chr16_17292069_-_GALNT6_chr12_51771151_length(transcript)=3378nt_BP=1374nt GCGGCCGCGGGAGCTGCGGGGAGCGCGGGGGCGGCCCGGAGCGTGCCGGGGTCCCCGCGCCTCGCTCGCCGGCCGCGCTCCGAAGATGGT GGCGGCGCCGTGCGCCCGGAGGCTGGCCCGGCGCTCGCACTCGGCGCTGCTCGCGGCGCTCACGGTGCTGCTGCTGCAGACGCTGGTCGT GTGGAATTTCAGCAGCCTCGACTCCGGGGCCGGGGAGCGCCGCGGGGGCGCAGCGGTCGGCGGCGGGGAGCAGCCGCCCCCGGCCCCGGC CCCGCGCCGGGAGCGCCGGGACCTGCCCGCCGAGCCGGCTGCAGCCCGAGGAGGAGGAGGAGGCGGCGGCGGAGGAGGAGGAGGACGGGG GCCCCAGGCGCGGGCGCGGGGAGGCGGCCCCGGAGAACCGCGGGGACAGCAGCCGGCCAGCCGGGGGGCACTGCCCGCCCGGGCTCTGGA TCCACACCCAAGTCCGCTCATCACCCTGGAGACTCAGGATGGCTACTTTTCTCATCGGCCGAAAGAGAAAGTGCGAACAGACAGCAACAA CGAGAACTCTGTCCCCAAAGACTTTGAGAATGTCGACAACAGCAACTTCGCACCCAGGACTCAAAAGCAGAAGCACCAGCCTGAGTTGGC GAAGAAGCCACCGAGTAGACAGAAGGAGCTTTTGAAAAGGAAGCTGGAACAGCAGGAGAAAGGAAAAGGACATACATTCCCTGGGAAAGG CCCCGGTGAGGTGCTGCCTCCCGGGGACAGAGCCGCAGCCAACAGCAGCCACGGGAAGGATGTGTCCAGACCGCCTCATGCCAGGAAAAC TGGGGGCAGCTCCCCCGAGACCAAGTATGACCAGCCCCCTAAGTGTGACATCTCAGGCAAGGAGGCCATCTCTGCCCTGTCCCGTGCTAA GTCCAAGCACTGCCGCCAGGAGATTGGGGAGACTTACTGCCGCCACAAGTTAGGGCTGCTGATGCCTGAGAAGGTGACTCGGTTCTGCCC CCTCGAGGGTAAAGCCAACAAGAACGTGCAGTGGGACGAGGACTCCGTGGAGTACATGCCAGCCAACCCGGTCAGAATCGCCTTTGTCCT GGTGGTCCACGGCCGTGCCTCTCGGCAGTTGCAGCGCATGTTCAAGGCCATCTACCACAAAGACCACTTCTACTACATCCACGTGGACAA GCGCTCTAATTACCTGCATCGGCAAGTGCTCCAGGTCTCCAGGCAGTACAGCAATGTCCGCGTCACCCCCTGGAGAATGGCCACCATCTG GGGAGGAGCCAGCCTCCTGTCCACCTACCTGCAGAGCATGCGGGACCTCCTGGAGATGACCGACTGGCCCTGGGACTTCTTCATCAACCT GAGTGCGGCCGACTACCCCATCAGGTGTGTGGACCAGAAGTTCCGGCGCTGCCCCCCACTGGCCACCACCAGCGTGATCATTGTGTTCCA CAACGAAGCCTGGTCCACACTGCTGCGAACAGTGTACAGCGTCCTACACACCACCCCTGCCATCTTGCTCAAGGAGATCATACTGGTGGA TGATGCCAGCACAGAGGAGCACCTAAAGGAGAAGCTGGAGCAGTACGTGAAGCAGCTGCAGGTGGTGAGGGTGGTGCGGCAGGAGGAGCG GAAGGGGCTGATCACCGCCCGGCTGCTGGGGGCCAGCGTGGCACAGGCGGAGGTGCTCACGTTCCTGGATGCCCACTGTGAGTGCTTCCA CGGCTGGCTGGAGCCCCTCCTGGCTCGAATCGCTGAGGACAAGACAGTGGTGGTGAGCCCAGACATCGTCACCATCGACCTTAATACTTT TGAGTTCGCCAAGCCCGTCCAGAGGGGCAGAGTCCATAGCCGAGGCAACTTTGACTGGAGCCTGACCTTCGGCTGGGAAACACTTCCTCC ACATGAGAAGCAGAGGCGCAAGGATGAAACCTACCCCATCAAATCCCCGACGTTTGCTGGTGGCCTCTTCTCCATCTCCAAGTCCTACTT TGAGCACATCGGTACCTATGATAATCAGATGGAGATCTGGGGAGGGGAGAACGTGGAAATGTCCTTCCGGGTGTGGCAGTGTGGGGGCCA GCTGGAGATCATCCCCTGCTCTGTCGTAGGCCATGTGTTCCGGACCAAGAGCCCCCACACCTTCCCCAAGGGCACTAGTGTCATTGCTCG CAATCAAGTGCGCCTGGCAGAGGTCTGGATGGACAGCTACAAGAAGATTTTCTATAGGAGAAATCTGCAGGCAGCAAAGATGGCCCAAGA GAAATCCTTCGGTGACATTTCGGAACGACTGCAGCTGAGGGAACAACTGCACTGTCACAACTTTTCCTGGTACCTGCACAATGTCTACCC AGAGATGTTTGTTCCTGACCTGACGCCCACCTTCTATGGTGCCATCAAGAACCTCGGCACCAACCAATGCCTGGATGTGGGTGAGAACAA CCGCGGGGGGAAGCCCCTCATCATGTACTCCTGCCACGGCCTTGGCGGCAACCAGTACTTTGAGTACACAACTCAGAGGGACCTTCGCCA CAACATCGCAAAGCAGCTGTGTCTACATGTCAGCAAGGGTGCTCTGGGCCTTGGGAGCTGTCACTTCACTGGCAAGAATAGCCAGGTCCC CAAGGACGAGGAATGGGAATTGGCCCAGGATCAGCTCATCAGGAACTCAGGATCTGGTACCTGCCTGACATCCCAGGACAAAAAGCCAGC CATGGCCCCCTGCAATCCCAGTGACCCCCATCAGTTGTGGCTCTTTGTCTAGGACCCAGATCATCCCCAGAGAGAGCCCCCACAAGCTCC TCAGGAAACAGGATTGCTGATGTCTGGGAACCTGATCACCAGCTTCTCTGGAGGCCGTAAAGATGGATTTCTAAACCCACTGGGTGGCAA GGCAGGACCTTCCTAATCCTTGCAACAACATTGGGCCCATTTTCTTTCCTTCACACCGATGGAAGAGACCATTAGGACATATATTTAGCC TAGCGTTTTCCTGTTCTAGAAATAGAGGCTCCCAAAGTAGGGAAGGCAGCTGGGGGAGGGTTCAGGGCAGCAATGCTGAGTTCAAGAAAA GTACTTCAGGCTGGGCACAGTGGCTCATGCCTGAAATCCTAGCACTTTGGGAAGACAATGTGGGAGAATGGCTTGAGCCCAGGAGTTCAA GACCGGCCTGAGCAACATAGTGAGGATCCCATCTCTACGCCCACCCTCCCCCCGGCAAAAAAAAAAAGCTGGGTATGGTGGCTTATGCCT GTAGTCGCAGCTACTCAGAAGGCTGAGGTGGGAGGATTGCTTGTTCCCCGGAGGTTGAAGCTACAGTGAGCCTTGATTGTGTCACTGCAC >In-frame_ENST00000261381_ENST00000356317_TCGA-DX-A1KU-01A_XYLT1_chr16_17292069_-_GALNT6_chr12_51771151_length(amino acids)=912AA_start in transcript=13_stop in transcript=2751 MRGARGRPGACRGPRASLAGRAPKMVAAPCARRLARRSHSALLAALTVLLLQTLVVWNFSSLDSGAGERRGGAAVGGGEQPPPAPAPRRE RRDLPAEPAAARGGGGGGGGGGGGRGPQARARGGGPGEPRGQQPASRGALPARALDPHPSPLITLETQDGYFSHRPKEKVRTDSNNENSV PKDFENVDNSNFAPRTQKQKHQPELAKKPPSRQKELLKRKLEQQEKGKGHTFPGKGPGEVLPPGDRAAANSSHGKDVSRPPHARKTGGSS PETKYDQPPKCDISGKEAISALSRAKSKHCRQEIGETYCRHKLGLLMPEKVTRFCPLEGKANKNVQWDEDSVEYMPANPVRIAFVLVVHG RASRQLQRMFKAIYHKDHFYYIHVDKRSNYLHRQVLQVSRQYSNVRVTPWRMATIWGGASLLSTYLQSMRDLLEMTDWPWDFFINLSAAD YPIRCVDQKFRRCPPLATTSVIIVFHNEAWSTLLRTVYSVLHTTPAILLKEIILVDDASTEEHLKEKLEQYVKQLQVVRVVRQEERKGLI TARLLGASVAQAEVLTFLDAHCECFHGWLEPLLARIAEDKTVVVSPDIVTIDLNTFEFAKPVQRGRVHSRGNFDWSLTFGWETLPPHEKQ RRKDETYPIKSPTFAGGLFSISKSYFEHIGTYDNQMEIWGGENVEMSFRVWQCGGQLEIIPCSVVGHVFRTKSPHTFPKGTSVIARNQVR LAEVWMDSYKKIFYRRNLQAAKMAQEKSFGDISERLQLREQLHCHNFSWYLHNVYPEMFVPDLTPTFYGAIKNLGTNQCLDVGENNRGGK PLIMYSCHGLGGNQYFEYTTQRDLRHNIAKQLCLHVSKGALGLGSCHFTGKNSQVPKDEEWELAQDQLIRNSGSGTCLTSQDKKPAMAPC -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for XYLT1-GALNT6 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for XYLT1-GALNT6 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for XYLT1-GALNT6 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | XYLT1 | C4014294 | DESBUQUOIS DYSPLASIA 2 | 4 | GENOMICS_ENGLAND;UNIPROT |
| Hgene | XYLT1 | C0013146 | Drug abuse | 1 | CTD_human |
| Hgene | XYLT1 | C0013170 | Drug habituation | 1 | CTD_human |
| Hgene | XYLT1 | C0013222 | Drug Use Disorders | 1 | CTD_human |
| Hgene | XYLT1 | C0029231 | Organic Mental Disorders, Substance-Induced | 1 | CTD_human |
| Hgene | XYLT1 | C0033847 | Pseudoxanthoma Elasticum | 1 | CTD_human;GENOMICS_ENGLAND;UNIPROT |
| Hgene | XYLT1 | C0038580 | Substance Dependence | 1 | CTD_human |
| Hgene | XYLT1 | C0038586 | Substance Use Disorders | 1 | CTD_human |
| Hgene | XYLT1 | C0236969 | Substance-Related Disorders | 1 | CTD_human |
| Hgene | XYLT1 | C0432242 | Desbuquois syndrome | 1 | CTD_human;ORPHANET |
| Hgene | XYLT1 | C0740858 | Substance abuse problem | 1 | CTD_human |
| Hgene | XYLT1 | C1510472 | Drug Dependence | 1 | CTD_human |
| Hgene | XYLT1 | C4316881 | Prescription Drug Abuse | 1 | CTD_human |
| Hgene | XYLT1 | C4750849 | XYLT1-CDG - xylosyltransferase 1 congenital disorder of glycosylation | 1 | ORPHANET |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies